Abstract Number: 2581 • ACR Convergence 2023
Proteomic Signatures in Pre-Rheumatoid Arthritis Suggest Evolving Biological Pathways in Different Stages of Disease Development That May Inform Prediction and Prevention Strategies
Background/Purpose: Rheumatoid arthritis (RA) includes a stage of development that can be termed 'pre-RA' and defined as the presence of abnormal biomarkers and/or other features…Abstract Number: 0962 • ACR Convergence 2023
Topological Proteomic Differences in Fibrotic and Unaffected Skin in Scleroderma
Background/Purpose: Scleroderma (SSc) is a chronic autoimmune and rheumatic disease characterized by varying levels of tissue fibrosis in the skin and other internal organs. It…Abstract Number: 2601 • ACR Convergence 2023
Identification of Giant Cell Arteritis Using Plasma Proteome Profiles Integrated with Machine Learning
Background/Purpose: The availability of diagnostic laboratory tests and specific biomarkers of disease activity for giant cell arteritis (GCA) remains an area of unmet need. The…Abstract Number: 1608 • ACR Convergence 2023
Plasma Proteomic Profiling in Antiphospholipid Antibody-positive Patients with Different Clinical Phenotypes: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with thrombotic and obstetric complications arising via a model of immunothrombosis. Patients may present with a spectrum…Abstract Number: 1633 • ACR Convergence 2023
Dose Dependent Modulation of a B Cell Protein Signature by Ianalumab in Patients with Sjögren’s Disease
Background/Purpose: Ianalumab (VAY736) is an afuscosylated monoclonal antibody targeting the B cell activating factor receptor (BAFFR) that depletes B cells via enhanced antibody dependent cellular…Abstract Number: 1637 • ACR Convergence 2023
IgG-Fc-N-Sialylation and -Galactosylation in Primary Sjögren’s Syndrome (Pss) in Its Potential as Marker of Disease State and Disease Activity
Background/Purpose: Loss of galactose and sialic acid structures attached to the IgG-Fc-fragment switches the antibody effector function from anti-inflammatory to pro-inflammatory1. This study investigated the…Abstract Number: 0020 • ACR Convergence 2023
The Inflammatory Proteome in Sjögren’s Syndrome Identifies New Biomarkers and Relevant Clinical Subgroups
Background/Purpose: Primary Sjögren's syndrome (pSS) is an autoimmune disease characterised by glandular involvement of the eye and salivary glands, leading to xerostomia and xerophthalmia. In…Abstract Number: 1696 • ACR Convergence 2023
Multi-Omic Profiling Reveals Immune Cell Priming Signature Linked to Systemic Lupus Erythematosus Prognosis
Background/Purpose: Much of our understanding of systemic lupus erythematosus (SLE) immunopathogenesis is derived from gene profiling studies, where core pathways such as neutrophil dysregulation and…Abstract Number: 0023 • ACR Convergence 2023
Proteomic Analysis of Plasma-derived Extracellular Vesicles Renders Glutathione Peroxidase 3 a Biomarker for Dermatomyositis
Background/Purpose: Extracellular vesicles (EVs) have been implicated in autoimmune disease pathogenesis. Plasma-derived DNA containing EVs have been shown to induce STING-mediated proinflammatory responses in dermatomyositis…Abstract Number: 1698 • ACR Convergence 2023
High-throughput Proteomics Identities a Spectrum of Novel Serum Biomarkers of Lupus Nephritis
Background/Purpose: Navigating the molecular complexity of lupus nephritis (LN), a heterogeneous autoimmune disorder, poses challenges to biomarker discovery. This study addresses these challenges through an…Abstract Number: 0659 • ACR Convergence 2022
Comprehensive Proteomic Screen of Murine Lupus Serum and Cerebrospinal Fluid Uncovers Diagnostic and Therapeutic Targets
Background/Purpose: Up to 50% of SLE patients experience neuropsychiatric involvement (neuropsychiatric lupus, or NPLSE) through an unknown mechanism. Diagnosis currently relies on clinical criteria and…Abstract Number: 0660 • ACR Convergence 2022
Serum Proteins and Metabolites Differ in SLE Patients with Coronary Microvascular Dysfunction (CMD) as Determined by Cardiac MRI Compared to SLE Patients Without CMD – a Pilot Study
Background/Purpose: Cardiovascular disease (CVD) is a significant cause of mortality in patients with SLE. While obstructive coronary artery disease (CAD) is a leading cause of…Abstract Number: 0909 • ACR Convergence 2022
Unsupervised Clustering Analysis of Circulating Molecular Profiles in Rheumatoid Arthritis Patients Defines Precise CV Risk. Effects of TNFi, IL6Ri, and JAKinibs
Background/Purpose: This study aimed to 1) Analyze the circulating inflammatory profile of Rheumatoid Arthritis (RA) patients, in order to recognize distinctive clinical phenotypes associated with…Abstract Number: 0975 • ACR Convergence 2022
Modulation of T, B, and Innate Cell-Associated Pharmacodynamic Biomarkers in a Phase 3 Trial of Anifrolumab in Moderate to Severe SLE
Background/Purpose: SLE has been associated with expression of type I IFN gene signatures (IFNGS).1 Anifrolumab, a monoclonal antibody binding IFN receptor subunit 1, inhibits downstream…Abstract Number: 1087 • ACR Convergence 2022
Identification of Novel Proteomic Biomarkers of Disease Activity in ANCA-Associated Vasculitis Using a High Throughput Approach
Background/Purpose: ANCA-associated vasculitis (AAV) is associated with excess morbidity and mortality. Identifying novel biomarkers may reveal new therapeutic targets and clinically useful biomarkers of disease…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 10
- Next Page »